# A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

> **NCT02377466** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Obstetric Labour, Premature

## Interventions

- **DRUG:** Retosiban IV infusion
- **DRUG:** Placebo IV infusion

## Key facts

- **NCT ID:** NCT02377466
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-29
- **Primary completion:** 2017-07-24
- **Final completion:** 2017-07-24
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Asset terminated by PIB
- **Last updated:** 2020-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02377466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02377466, "A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02377466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*